Abstract
Background:
This study aimed to investigate the role of regulatory T cells in patients with unexplained recurrent pregnancy loss (URPL).
Methods:
We retrospectively analyzed 136 women who had experienced two or more miscarriages before 24 weeks of gestation for no obvious reason from May 2018 to October 2021. The basic clinical data of the patients and expression of lymphocyte subsets such as regulatory T cells (Tregs) and natural killer cells (NKs) by flow cytometry were collected to explore the risk factors of pregnancy outcome in URPL patients.
Results:
A total of 136 URPL patients were enrolled in this study. Eventually, 50 patients attained clinical pregnancy. The median age was 31.8 ± 4.6 years in patients with clinical pregnancy. The univariate and multivariate logistic regression analyses indicated that Tregs was associated with the pregnancy outcomes of patients with URPL (odds ratio 0.63, 95% confidence interval 0.50–0.80). More importantly, a U-shaped association was found between Tregs and pregnancy outcome (p < 0.001), with either higher or lower Tregs levels adversely affecting pregnancy outcome.
Conclusion:
Tregs levels that are either too high or too low can harm pregnancy outcomes. It was expected to be a very promising quantitative biomarker for predicting pregnancy outcomes in URPL patients.
Introduction
Recurrent pregnancy loss (RPL) is defined as two or more miscarriages with the same sexual partner within 24 weeks of gestation, with a prevalence ranging from 1%–5% (1). In approximately 50% of patients with RPL, the underlying cause remains unknown, and 80% of unexplained miscarriages are closely related to immune factors (2). Due to poor pregnancy outcomes, patients with RPL often face great psychological and social pressure.
Among the known causes, immune factors, thrombophilia, anatomical abnormalities of the uterus and endocrine abnormalities are the 4 most important causes (3). Immunological factors are divided into autoimmunity and alloimmunity. Autoimmunity typically involves the presence of autoantibodies, resulting in tissue and organ damage and pregnancy loss. Clinical diagnosis involves testing for autoantibodies. Alloimmunity refers to the inability of the body to develop appropriate immune tolerance over a certain period, resulting in maternal rejection of the embryo and subsequent miscarriage (4). Because of the lack of a specific test, alloimmunization is still a controversial study, although there is growing evidence to support the possibility that RPL of unknown origin may be related to alloimmunization (5). However, there is still no clear and effective method to predict recurrent pregnancy loss of unknown origin.
At the placenta, natural killer cells (NKs) are the most prevalent form of lymphocyte. Placental NKs exhibit low cytotoxicity and can aid in the formation of blood vessels, in contrast to blood NK (6). Nevertheless, it has been noted that increased NKs activity is detrimental to pregnancy and associated with unexplained recurrent pregnancy loss (URPL) (7). Another crucial lymphocyte in the placenta is Tregs, known for their immunosuppressive role in preventing activated NKs and CD8+ T cells from causing harm (8). Tregs are generally amplified at the maternal-fetal interface and in peripheral blood after delivery (9). However, some studies had shown that URPL patients did not experience this amplification (10, 11). Although the majority of URPL patients seek medical attention when they are not pregnant, abnormal immune activation or a deficiency of immune cells during pregnancy appear to be connected to URPL. It’s still unclear whether the aberrant immunological state may be identified before pregnancy.
Indeed, some studies (12, 13) show that low levels of Tregs can harm pregnancy outcomes in URPL patients. However, the effect of high levels of Tregs on pregnancy outcomes in URPL patients is easily neglected. In our study, restrictive cubic spline (RCS) flexible modeling was used to explore the potential nonlinear correlation between the Tregs and the pregnancy outcomes in URPL.
Methods
Study design
We evaluated 136 patients in the database of the First Affiliated Hospital of Nanchang University who had experienced two or more unexplained miscarriages before 24 weeks of gestation from May 2018 to October 2021. Among them, 50 patients (the pregnancy group) had successful pregnancies, while 86 patients (the control group) experienced pregnancy losses. We compared basic clinical data, laboratory test results, and changes in lymphocyte subpopulations between the two groups. Additionally, we analyzed the risk factors for pregnancy outcomes in patients with URPL (a flow diagram of the study design is depicted in Figure 1).
Figure 1
Flow diagram for study population. RPL, recurrent pregnancy loss; URPL, unexplained recurrent pregnancy loss.
The following inclusion and diagnostic criteria and exclusion criteria were used for all enrolled patients. The inclusion criteria for patients were as follows: all patients met the diagnostic criteria for RPL as defined by the American Society for Reproductive Medicine (ASRM) (1); normal spousal semen examination; absence of abnormal karyotype in both spouses; the following exclusion criteria were also met: autoimmune diseases with positive autoantibodies; combined organic pelvic genital tract disease; cervical secretions with detectable reproductive tract infection; combined blood hypercoagulable state; combined ovarian tumors.
Detection
Fasting peripheral venous blood samples were collected from all patients with RPL and immediately sent to the Department of Laboratory Medicine of the First Affiliated Hospital of Nanchang University for testing. Lymphocyte subsets were detected by flow cytometry: specifically, Tregs (CD3+ CD4+ CD25+ CD127dim/−), CD4+ T cells (CD3+ CD4+) ratio, CD8+ T cells (CD3+ CD8+) ratio, B cells (CD3− CD19+) ratio, natural killer cells (NK cells; CD3− CD56+ CD16+) ratio, while recording their synchronized lymphocyte absolute results, and further calculating the absolute cell counts of each lymphocyte subpopulation.
Specific assay method: 50 μL of peripheral venous blood was collected, anticoagulated, and placed in an absolute counting tube, 15 μL of 6-color lymphocyte subpopulation antibody was added and mixed, incubated for 15 min, then 450 μL of hemolytic agent for flow cytometry was added, mixed thoroughly, and placed for 10 min in the dark, followed by centrifugation at 2,500 r/min (centrifugation radius 10 cm) for 6 min, the supernatant was removed, and 100 μL of PBS was added, it was done twice, and then put on the flow cytometer. The lymphocyte subpopulations in the blood specimens were detected using a BD FACSCANTO II flow cytometer (BD, United States). For regulatory T cells assay, 100 μL of whole blood anticoagulated with sodium heparin was taken, labeled anti-human CD4-FITC, and CD25-APC antibodies were added, incubated for 20 min at 4°C and protected from light, erythrocyte lysate was added, left at room temperature for 10 min, rinsed twice with PBS, add membrane breaking liquid and placed at 4°C in the dark for 1 h, rinsed twice with PBS, and detected by flow cytometry.
Nonlinear analysis
Nonlinear analysis is a versatile mathematical and statistical approach crucial for investigating relationships and phenomena that deviate from linear patterns. In comparison with generalized linear models, Nonlinear analysis can unveil the intricacies of real-world data, providing a comprehensive understanding of dynamic processes, and aiding in predictions, modeling, and decision-making. Especially in the context of generalized linear models, it is often assumed that the relationship between outcomes and variables is linear, yet this frequently overlooks the potential presence of nonlinear relationships between outcomes and variables. Therefore, in this study, we employed nonlinear analysis to investigate the underlying nonlinear relationship between the Tregs and the pregnancy outcome in URPL.
Statistical analysis
SPSS version 26.0 (IBM, Armonk, NY, United States) was used for statistical analysis. Continuous variables were described as the mean ± standard deviation for normally distributed data. Categorical variables were described as frequencies and percentages. For normally distributed continuous data, differences between the two groups were analyzed using an independent samples t-test. Categorical variables were evaluated using either the chi-square test or Fisher’s exact test to determine differences between the two groups. Pearson’s test was employed for the correlation analysis. Univariate and multivariate logistic regression analysis was applied for the analysis of the risk factors of pregnancy outcomes in URPL patients. Restrictive cubic spline (RCS) flexible modeling was used to explore the potential nonlinear correlation between the Tregs and the pregnancy outcome in URPL. All statistical tests were two-tailed, and p < 0.05 was considered statistically significant.
Results
Baseline characteristics
A total of 136 patients with URPL were included in this study, and the mean age of those with URPL was 31.7 ± 4.6 years. Among them, 50 patients (36.8%) had successful pregnancies; 86 patients (63.2%) had pregnancy losses. According to the report provided by the Clinical Laboratory Department of the First Affiliated Hospital of Nanchang University, the normal reference range for Tregs (as a proportion of total CD4+ cells) is 4 to 9. In our study, we observed that among 50 patients with successful pregnancies, only 8 had Tregs in the abnormal range, while among the 86 patients with pregnancy loss, 47 had Tregs in the abnormal range. Meanwhile, we found significant differences in Tregs and NK cells between the two groups (p < 0.05). The baseline characteristics and outcomes are shown in Table 1.
Table 1
| Total n = 136 | Successful pregnancies n = 50 | Pregnancy loss n = 86 | p-value | |
|---|---|---|---|---|
| Age, years | 31.7 ± 4.6 | 31.8 ± 4.6 | 31.7 ± 4.6 | 0.939 |
| Number of miscarriages | 0.795 | |||
| ≥3 | 39 (28.7%)a | 15 (30.0%)a | 24 (27.9%)a | |
| <3 | 97 (71.3%)a | 35 (70.0%)a | 62 (72.1%)a | |
| Tregs (abnormal)c | 55 (40.4%)a | 8 (16.0%)a | 47 (54.7%)a | <0.001 |
| <4 | 45 (33.1%)a | 3 (6.0%)b | 42 (48.9%)a | |
| >9 | 10 (7.3%)a | 5 (10.0%)a | 5 (5.8%)a | |
| CD3+ cells | 1245.5 ± 380.7 | 1309.3 ± 433.1 | 1218.6 ± 356.2 | 0.276 |
| CD3+ CD4+ cells | 661.0 ± 209.9 | 711.9 ± 246.3 | 639.5 ± 190.4 | 0.114 |
| CD3+ CD8+ cells | 464.2 ± 199.8 | 490.5 ± 201.3 | 453.1 ± 199.5 | 0.393 |
| CD4/CD8 ratio | 1.6 ± 0.6 | 1.5 ± 0.5 | 1.6 ± 0.6 | 0.811 |
| NK cells | 291.4 ± 175.5 | 234.5 ± 166.3 | 324.5 ± 173.1 | 0.004 |
| B cells | 215.3 ± 95.6 | 214.2 ± 71.9 | 215.8 ± 104.3 | 0.94 |
Baseline characteristics of all qualified participants.
Tregs, regulatory T cells; bold values are statistically significant (p < 0.05).
The categorical data were described as frequencies (percentages), and the differences between the two groups were tested by the chi-square test.
For categorical data with counts less than 5, differences between the two groups were tested by the Fisher’s exact test.
According to the report provided by the Clinical Laboratory Department of the First Affiliated Hospital of Nanchang University, the normal reference range for Tregs (as a proportion of total CD4+cells) is 4 to 9.
Correlation analysis between other lymphocyte subsets and Tregs
After correlation analyses between other lymphocyte subsets and Tregs in patients with URPL, it was found that Tregs was negatively correlated with NK cells (r = −0.262, p = 0.002). No other correlation analyses were found significant between other lymphocyte subsets and Tregs (Figure 2).
Figure 2
Correlation analysis between Tregs and NK cells.
Univariate and multivariate logistic regression analyses for pregnancy outcome
The univariate logistic regression analyses suggested that Tregs and NK cells might be associated with pregnancy outcomes (Table 2). After multivariate logistic regression analysis, the result indicated that Tregs (OR = 0.63, p < 0.001) were associated with the pregnancy outcomes of patients with URPL (Table 3).
Table 2
| Parameters | OR | 95% CI | p-value |
|---|---|---|---|
| Tregs | 0.60 | 0.49–0.73 | <0.001 |
| CD3+ cells | 1.00 | 1.00–1.00 | 0.275 |
| CD3+ CD4+ cells | 1.00 | 1.00–1.00 | 0.118 |
| CD3+ CD8+ cells | 1.00 | 1.00–1.00 | 0.392 |
| CD4/CD8 ratio | 1.10 | 0.51–2.38 | 0.809 |
| NK cells | 1.00 | 1.00–1.01 | 0.005 |
| B cells | 1.00 | 1.00–1.00 | 0.939 |
Univariate regression for effect of Tregs on pregnancy outcome.
Tregs, R regulatory T cells; OR, odds ratio; 95% CI, 95% confidence interval. Bold values are statistically significant (p < 0.05). Outcome variable: successful pregnancies. Two reference groups: successful pregnancies group and pregnancy loss group.
Table 3
| Parameters | OR | 95% CI | p-value |
|---|---|---|---|
| Age | 0.94 | 0.83–1.06 | 0.342 |
| Number of miscarriages | 0.65 | 0.21–2.02 | 0.455 |
| Tregs | 0.63 | 0.50–0.80 | <0.001 |
| CD3+ cells | 1.00 | 1.00–1.01 | 0.423 |
| CD3+ CD4+ cells | 0.99 | 0.98–1.00 | 0.093 |
| CD3+ CD8+ cells | 1.00 | 0.99–1.01 | 0.707 |
| CD4/CD8 ratio | 2.18 | 0.24–19.80 | 0.488 |
| NK cells | 1.00 | 0.99–1.00 | 0.330 |
| B cells | 1.01 | 1.00–1.01 | 0.059 |
Multivariate regression for effect of Tregs on pregnancy outcome.
Tregs, R regulatory T cells; OR, odds ratio; 95% CI, 95% confidence interval. Bold values are statistically significant (p < 0.05). Outcome variable: successful pregnancies. Two reference groups: successful pregnancies group and pregnancy loss group.
Nonlinear relationship between Tregs and the pregnancy outcomes
In Figure 3, a nonlinear relationship was observed for the first time between Tregs and the pregnancy outcomes of patients with URPL (p < 0.001). The results of the nonlinear analysis showed a U-shaped distribution of the effect of Tregs on pregnancy outcome, with either higher or lower Treg cell levels adversely affecting pregnancy outcome.
Figure 3
Nonlinear relationship between Tregs and the pregnancy outcomes of patients with URPL.
Discussion
In recent years, the number of patients with URPL has gradually increased, and women with a history of multiple miscarriages are under great physical and psychological stress. Effective treatment options to regulate immune function to prevent miscarriage are under intensive research. The evolving understanding of reproductive immunity has linked the etiology of recurrent miscarriage to immune disorders. It is now acknowledged that approximately 50%–60% of recurrent miscarriages are associated with immunological factors (2). Of these, around 2/3 fall into the category of alloimmune-type recurrent miscarriage. This subgroup comprises patients with URPL experiencing an alloimmune state characterized by an imbalance at the maternal-fetal interface, leading to intrinsic or acquired immune disorders. Examples include abnormalities in NK cells, Th1/Th2 cell imbalance, imbalances in the Th17 cell subpopulation and Tregs, and other immune disorders. Importantly, these disorders do not cause systemic organ tissue damage in pregnant women (14). It is important to explore the impact of immune disorders, immunotherapy, and some other indicators on pregnancy outcomes in these patients to clinically guide the treatment of URPL patients.
Regulatory T cells, also known as Tregs, are a subset of CD4+ T helper cells that suppress the immune system (15). Through interactions with target cells, secretion of anti-inflammatory cytokines like IL-10, competition with CTL cell inducer IL-2 for occupancy, and other mechanisms, Tregs effectively control local inflammatory responses (16). Thus, it is a cell type with potent immunosuppressive activity. Antigenic stimulus is necessary for Treg activation, just like it is for other T cells. A study discovered that following fetal implantation, Tregs in the decidua and peripheral blood rapidly grew as a result of embryonic antigen stimulation (17), but a different study indicated that URPL patients did not experience this increase (10, 11). In a DBA × CBA abortion model, adoptive infusion of Tregs from pregnant mice saved embryos from resorption (18). According to all available research, the failure of Tregs to expand throughout pregnancy may be connected to the phenomena of recurrent miscarriage, which shows that Tregs are essential for maintaining immunological tolerance at the maternal-fetal interface.
The quantity and function of Tregs may undergo changes during pregnancy to accommodate the maternal immune system’s tolerance towards the fetus. During early pregnancy (first to third month), Treg cell levels are relatively low. This is primarily to avoid excessive suppression of immune responses and to maintain defense against pathogens (19). During this period, cells in the placenta produce a series of molecular signals to suppress the maternal immune system, thus protecting the embryo’s survival. As pregnancy progresses into the mid-term (fourth to sixth month), Tregs gradually increase. This increase may help in suppressing autoimmune responses, reducing immune attacks on the fetus, and maintaining normal fetal development (20). By late pregnancy (seventh to ninth month), the levels of Tregs further increase. This increase may contribute to protecting the fetus from immune-related complications, such as intrauterine growth restriction and preterm birth. In our study, all Tregs measurements of enrolled patients were conducted within 1–2 weeks prior to the next pregnancy. This avoids the Tregs detection discrepancies caused by different stages of pregnancy.
It is noteworthy that previous studies have suggested differences in the distribution of Tregs between the decidua and peripheral blood (21, 22). The study by Tilburgs et al. (23) revealed Tregs to be much more abundant in decidual samples compared to peripheral blood samples in pregnant patients. Moreover, their findings demonstrated a markedly elevated proportion of Tregs in the decidua parietalis in contrast to the decidua basalis. Regrettably, constrained by technical limitations, this study conducted detection of Tregs in the peripheral blood. Subsequent assessments of Tregs in the placenta are essential to further validate the findings of this study.
Indeed, many researchers have reported that women with URPL have lower Tregs levels than normal patients (24, 25). Up to now, numerous results generally suggest that lower Tregs level is associated with a higher risk of miscarriage in women with URPL (12, 13, 26). However, our study revealed for the first time that either lower or higher Tregs levels increase the risk of miscarriage in women with URPL. We found the effect of Tregs on pregnancy outcome has a U-shaped distribution, which is different from the results of many previous studies. On the one hand, the reduced number of blood Tregs may be a manifestation of impaired Treg amplification. Two types of Tregs are produced in different ways. Firstly, the production of natural Treg (nTreg) is thymus dependent (27, 28). Secondly, under the induction of TGF-β and other cytokines, naive T cells can differentiate into Tregs that show high expression of Foxp3 (29, 30). Following semen and embryonic antigen stimulation, Tregs expand rapidly during the first trimester of pregnancy. In fact, this expansion of Tregs is important in maintaining immune tolerance, and therefore failure of expansion may be a cause of miscarriage.
On the other hand, Tregs also have many subtypes (31), among which we speculate that both Tregs subtypes with immunosuppressive effects and Tregs subtypes with pro-inflammatory effects exist. Therefore, when Tregs levels are too high, immune tolerance at the maternal-fetal interface can also be influenced, leading to adverse pregnancy outcomes. A study by Professor Takuro Saito indicated that Tregs can be divided into three subpopulations based on FOXP3 and CD45RA expression levels. After being stimulated by an antigen, Fraction I (Fr-I; FOXP3loCD45RA+; also known as naive Treg (nTreg)) cells differentiate into Fraction II (FOXP3hiCD45RA+; also known as effector Treg (eTreg)) cells, which are terminally differentiated, highly suppressive, and functionally stable. Fr-III (FOXP3loCD45RA−) cells, in contrast, lack suppressive function and are capable of secreting pro-inflammatory cytokines (32). The above findings provided us with a strong support for the analysis of the results.
We acknowledge the potential limitations of our study. First, although our study revealed for the first time that either lower or higher Tregs levels increase the risk of miscarriage in women with URPL, we did not deeply explore the specific reasons. We will conduct in-depth analyses on different Tregs subpopulations in subsequent studies to clarify the specific mechanisms of the effect of lower or higher Tregs levels on pregnancy outcomes. Second, this study is a preliminary exploratory study, and we next hope to conduct a prospective, large sample study to further confirm the validity of Tregs level in predicting the risk of miscarriage in women with URPL.
Conclusion
We revealed for the first time a deeper nonlinear relationship between Tregs and the pregnancy outcomes of patients with URPL. More importantly, Tregs was expected to be a very promising quantitative biomarker for predicting pregnancy outcomes in URPL patients.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving humans were approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University. The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants’ legal guardians/next of kin because the requirement for informed consent from the study participants was waived in accordance with local legislation and institutional requirements.
Author contributions
P-cL and RW: study design and drafting of the manuscript. J-bL and Y-pH: data collection and interpretation. P-cL and MZ: data analysis. J-bL, Y-pH, and S-jY: modification and polishing. All authors contributed to the article and approved the submitted version.
Funding
This study was supported by a grant from the National Natural Science Foundation of China (No. 82260898) and the Natural Science Foundation of Jiangxi Province (No. 20192BAB205122).
Acknowledgments
The authors thank all the study participants for their approval and cooperation to accomplish this study. The authors would like to thank Zoe Zeng for her help with langue editing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
Practice Committee of the American Society for Reproductive Medicine . Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. (2012) 98:1103–11. doi: 10.1016/j.fertnstert.2012.06.048
2.
Abdollahi E Tavasolian F Ghasemi N Mirghanizadeh SA Azizi M Ghoryani M et al . Association between lower frequency of R381Q variant (rs11209026) in IL-23 receptor gene and increased risk of recurrent spontaneous abortion (RSA). J Immunotoxicol. (2015) 12:317–21. doi: 10.3109/1547691X.2014.978056
3.
Deng T Liao X Zhu S . Recent advances in treatment of recurrent spontaneous abortion. Obstet Gynecol Surv. (2022) 77:355–66. doi: 10.1097/OGX.0000000000001033
4.
Ander SE Diamond MS Coyne CB . Immune responses at the maternal-fetal interface. Sci Immunol. (2019) 4:eaat6114. doi: 10.1126/sciimmunol.aat6114
5.
Wong LF Porter TF Scott JR . Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev. (2014) 10:Cd000112. doi: 10.1002/14651858.CD000112.pub3
6.
Hanna J Goldman-Wohl D Hamani Y Avraham I Greenfield C Natanson-Yaron S et al . Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. (2006) 12:1065–74. doi: 10.1038/nm1452
7.
Seshadri S Sunkara SK . Natural killer cells in female infertility and recurrent miscarriage: a systematic review and meta-analysis. Hum Reprod Update. (2014) 20:429–38. doi: 10.1093/humupd/dmt056
8.
Hill JA Benoist C Mathis D . Treg cells: guardians for life. Nat Immunol. (2007) 8:124–5. doi: 10.1038/ni0207-124
9.
Salvany-Celades M van der Zwan A Benner M Setrajcic-Dragos V Bougleux Gomes HA Iyer V et al . Three types of functional regulatory T cells control T cell responses at the human maternal-fetal Interface. Cell Rep. (2019) 27:2537–2547.e5. doi: 10.1016/j.celrep.2019.04.109
10.
Mei S Tan J Chen H Chen Y Zhang J . Changes of CD4+ CD25 high regulatory T cells and FOXP3 expression in unexplained recurrent spontaneous abortion patients. Fertil Steril. (2010) 94:2244–7. doi: 10.1016/j.fertnstert.2009.11.020
11.
Inada K Shima T Ito M Ushijima A Saito S . Helios-positive functional regulatory T cells are decreased in decidua of miscarriage cases with normal fetal chromosomal content. J Reprod Immunol. (2015) 107:10–9. doi: 10.1016/j.jri.2014.09.053
12.
Wang W Zhao Y Zhou X Sung N Chen L Zhang X et al . Dynamic changes in regulatory T cells during normal pregnancy, recurrent pregnancy loss, and gestational diabetes. J Reprod Immunol. (2022) 150:103492. doi: 10.1016/j.jri.2022.103492
13.
Wang W Zhou X Zhang Y Chen Z Huang J Zhang X et al . The characteristics of antigenic specificity of memory regulatory t cells in women with unexplained recurrent pregnancy loss. J Reprod Immunol. (2022) 154:103694. doi: 10.1016/j.jri.2022.103694
14.
Martinet L Smyth MJ . Balancing natural killer cell activation through paired receptors. Nat Rev Immunol. (2015) 15:243–54. doi: 10.1038/nri3799
15.
Koizumi SI Ishikawa H . Transcriptional regulation of differentiation and functions of effector T regulatory cells. Cells. (2019) 8:939. doi: 10.3390/cells8080939
16.
Sakaguchi S Wing K Onishi Y Prieto-Martin P Yamaguchi T . Regulatory T cells: how do they suppress immune responses?Int Immunol. (2009) 21:1105–11. doi: 10.1093/intimm/dxp095
17.
Tsuda S Nakashima A Shima T Saito S . New paradigm in the role of regulatory T cells during pregnancy. Front Immunol. (2019) 10:573. doi: 10.3389/fimmu.2019.00573
18.
Wang J Yang J Yan Y Zhu Z Mu Y Wang X et al . Effect of adoptive transfer of CD4+ CD25+ Foxp3+ Treg induced by trichostatin a on the prevention of spontaneous abortion. J Reprod Immunol. (2019) 131:30–5. doi: 10.1016/j.jri.2018.12.002
19.
Xiong H Zhou C Qi G . Proportional changes of CD4+ CD25+ Foxp3+ regulatory T cells in maternal peripheral blood during pregnancy and labor at term and preterm. Clin Invest Med. (2010) 33:E422. doi: 10.25011/cim.v33i6.14594
20.
Quinn KH Lacoursiere DY Cui L Bui J Parast MM . The unique pathophysiology of early-onset severe preeclampsia: role of decidual T regulatory cells. J Reprod Immunol. (2011) 91:76–82. doi: 10.1016/j.jri.2011.05.006
21.
Tilburgs T Roelen DL van der Mast BJ de Groot-Swings GM Kleijburg C Scherjon SA et al . Evidence for a selective migration of fetus-specific CD4+ CD25 bright regulatory T cells from the peripheral blood to the decidua in human pregnancy. J Immunol. (2008) 180:5737–45. doi: 10.4049/jimmunol.180.8.5737
22.
Quinn KH Parast MM . Decidual regulatory T cells in placental pathology and pregnancy complications. Am J Reprod Immunol. (2013) 69:533–8. doi: 10.1111/aji.12077
23.
Tilburgs T Roelen D Vandermast B Vanschip J Kleijburg C Degrootswings G et al . Differential distribution of CD4+ CD25 bright and CD8+ CD28− T-cells in decidua and maternal blood during human pregnancy. Placenta. (2006) 27:47–53. doi: 10.1016/j.placenta.2005.11.008
24.
Ji J Zhai H Zhou H Song S Mor G Liao A . The role and mechanism of vitamin D-mediated regulation of Treg/Th17 balance in recurrent pregnancy loss. Am J Reprod Immunol. (2019) 81:e13112. doi: 10.1111/aji.13112
25.
Arruvito L Sanz M Banham AH Fainboim L . Expansion of CD4+ CD25+ and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction. J Immunol. (2007) 178:2572–8. doi: 10.4049/jimmunol.178.4.2572
26.
Bahia W Zitouni H Kanabekova P Bauyrzhanova Z Shaimardanova M Finan RR et al . Human forkhead box protein 3 gene variants associated with altered susceptibility to idiopathic recurrent pregnancy loss: a retrospective case-control study. Am J Reprod Immunol. (2022) 88:e13551. doi: 10.1111/aji.13551
27.
Hippen KL Hefazi M Larson JH Blazar BR . Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease. Front Immunol. (2022) 13:926550. doi: 10.3389/fimmu.2022.926550
28.
Cebula A Seweryn M Rempala GA Pabla SS McIndoe RA Denning TL et al . Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. Nature. (2013) 497:258–62. doi: 10.1038/nature12079
29.
Milanez-Almeida P Meyer-Hermann M Toker A Khailaie S Huehn J . Foxp3+ regulatory T-cell homeostasis quantitatively differs in murine peripheral lymph nodes and spleen. Eur J Immunol. (2015) 45:153–66. doi: 10.1002/eji.201444480
30.
Qu Y Zhang B Liu S Zhang A Wu T Zhao Y . 2-Gy whole-body irradiation significantly alters the balance of CD4+ CD25− T effector cells and CD4+ CD25+ Foxp3+ T regulatory cells in mice. Cell Mol Immunol. (2010) 7:419–27. doi: 10.1038/cmi.2010.45
31.
Masuda K Kornberg A Miller J Lin S Suek N Botella T et al . Multiplexed single-cell analysis reveals prognostic and nonprognostic T cell types in human colorectal cancer. JCI Insight. (2022) 7:e154646. doi: 10.1172/jci.insight.154646
32.
Saito T Nishikawa H Wada H Nagano Y Sugiyama D Atarashi K et al . Two FOXP3+ CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. (2016) 22:679–84. doi: 10.1038/nm.4086
Summary
Keywords
recurrent pregnancy loss, pregnancy outcome, regulatory T cells, U-shaped association, biomarker
Citation
Liu P-c, Li J-b, Huang Y-p, Zhang M, Yu S-j and Wu R (2024) Overexpression of regulatory T cells in patients with unexplained recurrent pregnancy loss: friend or foe?. Front. Med. 10:1244424. doi: 10.3389/fmed.2023.1244424
Received
23 June 2023
Accepted
14 December 2023
Published
04 January 2024
Volume
10 - 2023
Edited by
Panicos Shangaris, King’s College London, United Kingdom
Reviewed by
Kahindo P. Muyayalo, University of Kinshasa, Democratic Republic of Congo; Norma Galindo-Sevilla, Instituto Nacional de PerinatologÃa (INPER), Mexico
Updates
Copyright
© 2024 Liu, Li, Huang, Zhang, Yu and Wu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rui Wu, ndyfy00400@ncu.edu.cn
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.